Mineralys Therapeutics, Inc. MLYS U.S. federal, state and foreign net operating loss, credit carryforwards and other carryforwards
U.S. federal, state and foreign net operating loss, credit carryforwards and other carryforwards at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic.
The official record: Mineralys Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s u.s. federal, state and foreign net operating loss, credit carryforwards and other carryforwards.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s U.S. federal, state and foreign net operating loss, credit carryforwards and other carryforwards?
- Mineralys Therapeutics, Inc. (MLYS) reported U.S. federal, state and foreign net operating loss, credit carryforwards and other carryforwards of $244.6M in Q4 2025.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s U.S. federal, state and foreign net operating loss, credit carryforwards and other carryforwards?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s U.S. federal, state and foreign net operating loss, credit carryforwards and other carryforwards has grown at a 111.9% compound annual growth rate (CAGR), from $25.7M to $244.6M.